Wood creosote, the principal ingredient in Seirogan, has a long history as a known gastrointestinal microbicidal agent. When administered orally, the intraluminal concentration of wood creosote is not su‹ciently high to achieve this microbicidal eŠect. Through further animal tests, we have shown that antimotility and antisecretory actions are the principal antidiarrheal eŠects of wood creosote. Wood creosote inhibits intestinal secretion induced by enterotoxins by blocking the Cl -channel on the intestinal epithelium. Wood creosote also decreases intestinal motility accelerated by mechanical, chemical, or electrical stimulus by the inhibition of the Ca 2＋ in‰ux into the smooth muscle cells. In this overview, the antimotility and antisecretory eŠects of wood creosote are compared with those of loperamide. Wood creosote was observed to inhibit stimulated colonic motility, but not normal jejunal motility. Loperamide inhibits normal jejunal motility, but not stimulated colonic motility. Both wood creosote and loperamide inhibit intestinal secretion accelerated by acetylcholine. Wood creosote was found to have greater antisecretory eŠects in the colon than loperamide. Based upon theseˆndings, we conclude that the antidiarrheal eŠects of wood creosote are due to both antisecretory activity in the intestine and antimotility in the colon, but not due to the microbicidal activity as previously thought. Wood creosote was found to have no eŠects on normal intestinal activity. These conclusions are supported by the results of a recent clinical study comparing wood creosote and loperamide, which concluded that wood creosote was more e‹cacious in relieving abdominal pain and comparable to loperamide in relieving diarrhea.
Time course of the increase in MQAE ‰uorescence in CFTR (＋) cells (○, •) and CFTR (-) cells (△, ▲) loaded with MQAE after addition of 25 mmol/ml CPT-cAMP in the presence (•, ▲) or absence (○, △) of 30 mg/ml wood creosote. As MQAE ‰uorescence is quenched by Cl -, its intensity is inversely related to intracellular Cl -concentration. Time course intensity above the basal level (mF) after the addition of CPT-cAMP is shown. Each point represents the mean ＋/-S.E. ofˆve samples.  p＜0.05 and   p ＜0.01 versus vehicle (two-tailed unpaired Student's t test). . of adverse events  3  3  5  2  8  12  9  21  3  No. of subjects with adverse events  2  1  2  2  4  7  4  11  3 CK: creatine kinase, AST: aspartate aminotransferase, ALT: alanine aminotransferase. Column numbers may not add up to total number of subjects, as individual subjects may have reported more than one adverse event. Placebo group considered of all men. 
